Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Amylin is a hormone co-secreted with insulin in the pancreas that has anorexigenic effects, since it promotes satiety and reduces food intake. Amylin analogs and dual agonists of the amylin and ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

DelveInsight's Short-Acting Insulin Market Insights report provides the current and forecast market analysis, individual ...

Representational Photo The exploration of novel peptides for their potential impact on metabolic pathways has been a ...